A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
Phase of Trial: Phase I/II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Everolimus (Primary) ; Lenvatinib (Primary)
- Indications CNS cancer; Ewing's sarcoma; Glioma; Neuroectodermal tumours; Rhabdomyosarcoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Inc
- 04 Jan 2018 Planned primary completion date changed from 31 Mar 2022 to 30 Jun 2022.
- 04 Jan 2018 Status changed from not yet recruiting to recruiting.
- 14 Aug 2017 New trial record